We prioritized p53-repressive targets, since p53 mutations are common in cancers where p53-repressed genes are likely to be up-regulated, and if those gene products contribute to tumorigenesis, they may provide good candidates for therapeutic targets in p53-deficient cancers. This evidence concerns the gene TP53 and cancer.